Trial Profile
A Phase 1/2 Dose-escalation of USL311 as Single Agent and in Combination With Lomustine (CCNU) in Subjects With Advanced Solid Tumors, With Subsequent Single Agent and Combination Phase 2 Cohorts for Subjects With Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 31 Jul 2020
Price :
$35
*
At a glance
- Drugs USL 311 (Primary) ; Lomustine
- Indications Glioblastoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Proximagen; Upsher-Smith
- 28 Jul 2020 Status changed from recruiting to discontinued.
- 15 Jan 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Sep 2022.
- 15 Jan 2019 Status changed from active, no longer recruiting to recruiting.